Immunoneutralization studies with a monoclonal antibody to somatomedin C (Sm-C) were undertaken to further determine the role of this peptide in cellular proliferation. For our model we used density-arrested cultures of BALB/c 3T3 cells. Transient exposure of these cells to plateletderived growth factor enables them to respond to platelet-poor plasma by progressing through the G, stage and undergoing renewed DNA synthesis. In this system, the combination of nanogram concentrations of Sm-C and epidermal growth factor can fully substitute for plasma, and microgram concentrations of insulin can substitute for Sm-C by crossreacting with the Sm-C receptor. We now show that a monoclonal antibody to Sm-C, which in defined medium blocks the mitogenic effect of Sm-C but not insulin, also blocks the stimulation of DNA synthesis by human plasma or calf serum. Furthermore, by adding the antibody at progressively later times during G1, we show that these cells escape from their dependence on Sm-C for DNA synthesis after traversing GI to a point at or near the G1/S boundary.
BALB/c 3T3 cells. Transient exposure of these cells to plateletderived growth factor enables them to respond to platelet-poor plasma by progressing through the G, stage and undergoing renewed DNA synthesis. In this system, the combination of nanogram concentrations of Sm-C and epidermal growth factor can fully substitute for plasma, and microgram concentrations of insulin can substitute for Sm-C by crossreacting with the Sm-C receptor. We now show that a monoclonal antibody to Sm-C, which in defined medium blocks the mitogenic effect of Sm-C but not insulin, also blocks the stimulation of DNA synthesis by human plasma or calf serum. Furthermore, by adding the antibody at progressively later times during G1, we show that these cells escape from their dependence on Sm-C for DNA synthesis after traversing GI to a point at or near the G1/S boundary.
The somatomedins are a family of polypeptide hormones that mediate many of the growth promoting actions of growth hormone (1) (2) (3) . Somatomedin C (Sm-C) and insulinlike growth factor I (IGF-I) are synonyms for a single-chain 70-amino acid basic somatomedin that is more growth-hormone dependent and more mitogenic than the other human somatomedin, insulin-like growth factor II. The latter is a neutral molecule that is more insulin-like in its actions and is present at levels 3 times greater than those of Sm-C/IGF-I. Sm-C will restore linear growth in either hypophysectomized rats or in mice with a hereditary form of hypopituitarism (Snell dwarf strain) (4, 5) . Although nanogram concentrations of Sm-C have been reported to promote DNA synthesis and/or cell replication in many different cell types, the most detailed studies have been made in mouse mesenchyme-derived BALB/c 3T3 cells (6) . These cells, which become quiescent after having been grown to confluency in 10% serum, will respond to fresh serum-containing medium by progressing through the G1 stage and undergoing renewed DNA synthesis. Platelet-poor plasma (PPP), which is prepared by removing formed blood elements before clotting takes place, will not stimulate these quiescent cells to traverse G1 unless they are first exposed to platelet-derived growth factor (PDGF) (7). Stiles et al. (8) showed that PPP from hypophysectomized rats was ineffectual in stimulating DNA synthesis unless supplemented with added Sm-C. More recently, Leof et al. (9, 10) have shown that a combination of Sm-C and epidermal growth factor (EGF) can completely replace plasma in permitting PDGF-treated cells to progress to DNA synthesis. At high doses (1 AsM), insulin can serve as a somatomedin surrogate by binding to the Sm-C receptor (11) . The
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Thymidine incorporation was determined after the monolayers were rinsed in serum-free DME medium/F-12, fixed and washed twice in 5% trichloroacetic acid at 4°C and then solubilized in 0.1 M NaOH with 1% sodium dodecyl sulfate for counting. All results are expressed as the mean of tnrplicate wells ± SEM. In some experiments, autoradiography was performed according to the method of Antoniades et al. (12) .
Growth Factors and Sera. Sm-C was purified from human plasma by the method of Svoboda et al. (13) . The preparation used in this study was a pool of side fractions from the terminal HPLC purification step. PDGF was prepared from heated extracts of clinically outdated human platelets chromatographed on CM Sephadex, followed by further purification on Blue Sepharose and Bio-Gel 150 as described (14, 15) . EGF was prepared by the method of Savage and Cohen (16) , and was the gift of E. O'Keefe. Human PPP (inactivated at 56°C for 30 min) was prepared as described by Pledger et al. (7) and calf serum was purchased from Hyclone (Logan, UT). Monoclonal Antibody to Sm-C (sm-1.2). The monoclonal antibody to Sm-C was produced in a mouse hyperimmunized over 6 weeks with highly purified Sm-C conjugated to mouse albumin. Prior to fusion with P3X63Ag8.653 myeloma cells, the splenocytes were boosted in vitro by a 5-day reexposure to pure Sm-C in thymocyte-conditioned medium. Anti-soma- tomedin-producing hybrids were cloned and amplified by intraperitoneal injection into pristane-primed BALB/c mice. The immunoglobulin fraction from the clone designated sm-1.2 was further purified from ascites fluid by sequential precipitation in 18% and 15% sodium sulfate (17) .
The antibody was a K IgG1 and bound Sm-C with an affini- (Fig. 1B) , sm-1.2 produced a comparable inhibition of Sm-C-dependent labeling as that depicted in Fig.   1A . However, the antibody failed to influence the labeling observed when 1 gg of insulin per ml was used as a somatomedin surrogate. This is in keeping with the previously documented high specificity of the antibody for Sm-C. These results (Fig. 1) were identical whether soluble antibody was incorporated directly into the incubation medium or whether the experimental media were preincubated with Sepharose-bound sm-1,2 to remove the growth factor prior to exposure of the cells. Thus, the affinity of the antibody for Sm-C appears to be sufficiently high that the growth factor need not be physically removed from the solution to be rendered inactive. Sm-C (ng/ml)
The effects of excess Sm-C on the inhibitory effect of monoclonal antibody. Thymidine incorporation was determined as described in the text. After exposure to PDGF for 5 hr, increasing amounts of Sm-C were added to cultures containing EGF (10 ng/ml) and sm-1.2 (1:4000).
The inhibitory effect of the Sm-C antibody on DNA synthesis could be overcome by the addition of excess Sm-C. Fig. 2 shows that Sm-C at 40-50 ng/ml fully restored the mitogenic activity of culture medium containing EGF at 10 ng/ml and sm-1.2 at 1 ,ug/ml. To exclude the possibility that the inhibitory effect of the monoclonal antibody might be due to some other factor in the ascites fluid and not to the antibody, we tested the effect of a similarly processed IgG monoclone to horse apoferritin and observed no inhibition of the stimulatory effect of Sm-C and EGF or of PPP (data not shown).
The antibody was as effective in inhibiting the activity of 5% human plasma as it was against the combination of Sm-C and EGF. Complete inhibition of the mitogenic effect of human plasma was evident up to a plasma concentration of 10% (Fig. 3A) . The antibody also decreased the potency of calf serum (Fig. 3B ), but this effect was less complete. We attribute these differences between human plasma and calf serum to the presence of PDGF in calf serum since the re-B quirement of these cells for plasma (or Sm-C) is progressively decreased with increasing concentrations of PDGF (7) . These data lend strong support to the hypothesis that Sm-C is a necessary component of plasma for the promotion of growth in cultured cells.
A consistent finding in our studies was that sm-1.2 produced a small inhibition of the DNA synthesis induced by EGF alone (Table 1 ). Since Leof et al. (10) found that EGF could not support the progression of BALB/c 3T3 cells through the early phases of G1 unless low concentrations of Sm-C were simultaneously present, and since Sm-C is produced by many cell types in vitro (18) , we postulated that the small inhibition of DNA synthesis caused by the antibody when only EGF was added to the medium was due to an inhibitory effect of the antibody on small amounts of endogenous Sm-C produced by the cells themselves. This was confirmed by finding that low but significant concentrations of immunoreactive Sm-C accumulate in the medium of densityinhibited BALB/c 3T3 cells cultured in the presence of PDGF and EGF (data not shown). This interpretation is further supported by the failure of the antibody to block the mitogenic effect of EGF in the presence of insulin when added in sufficiently high concentrations to serve as a Sm-C surrogate ( Fig. 1B and Table 1 ).
To determine whether at some point in G1 commitment to DNA synthesis no longer requires the presence of Sm-C, we added the monoclonal antibody at progressively later time intervals to the medium of PDGF-primed cells containing a combination of EGF and Sm-C and measured the rate of thymidine incorporation over 28 hr as described in Fig. 1A . As shown in Fig. 4 , addition of the antibody at any time prior to hr 9 after adding Sm-C and EGF completely prevented entry into DNA synthesis; thereafter, an increasing percentage of the cells entered the S phase. Since the minimum transit time through G1 after the addition of EGF and Sm-C is 10 hr in the absence of plasma (9), it can be concluded that irrevocable way for its use to determine the biological role of the somatomedins in the growth of living animals.
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